Appearance
White Powder
Source
Synthetic
Assay
(HPLC): Not less than 98.0%
1239908-20-3
C20H23BCl2N2O9
517.12
Ixazomib is able to inhibit the chymotrypsin-like proteolytic (β5) site of the 20S proteasome, and at higher concentrations inhibit the caspase-like (β1) and trypsin-like (β2) proteolytic sites.
2-8°C
White Powder
Synthetic
(HPLC): Not less than 98.0%